DMPI, DelMAR Pharma Break Out and Short Squeeze
DMPI has broken resistance on positive interim results of its clinical cancer drug, VAL-083. Analyst have a price target of $12. Bullish price action on trend analysis, chart patterns, and shorts covering.
相关出版物
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。